Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.107.047951 | DOI Listing |
Med Clin (Barc)
January 2025
Servicio de Endocrinología y Nutrición, Hospital i Institut de Recerca Germans Trias i Pujol, Universitat Autònoma de Barcelona, España. Electronic address:
In recent decades, the diagnosis of thyroid cancer, especially the papillary type, has increased significantly due to the use of imaging techniques such as ultrasound. For this reason, it is essential to rationalize diagnosis and treatment, since the behavior of thyroid cancer varies from slow-progressing tumors to highly aggressive ones. The application of risk assessment systems for ultrasound images and the optimization of cytology incorporating molecular studies allows cases to be stratified in order to select therapy on an individual basis.
View Article and Find Full Text PDFBr J Radiol
January 2025
Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical incications of the available agents.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:
The hypothalamic-pituitary-thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial thyroid cancer. Supraphysiological doses of levothyroxine are used in patients with intermediate-risk and high-risk thyroid cancer to suppress thyroid-stimulating hormone (TSH) to prevent tumour progression. However, free thyroxine and tri-iodothyronine have also been found to promote tumour growth in thyroid cancer preclinical models.
View Article and Find Full Text PDFThyroid
January 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
The study aimed to analyze the long-term outcomes of [Lu]Lu-DOTAGA.FAPi dimer therapy in individuals diagnosed with radioiodine-resistant (RAI-R) follicular cell-derived thyroid cancer. In this retrospective study, 73 patients with RAI-R follicular thyroid carcinoma who had undergone multiple lines of previous treatments were included.
View Article and Find Full Text PDFInt J Womens Health
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Background: Clear cell ovarian carcinoma (CCOC) is a type of epithelial ovarian cancer, representing 5-11% of ovarian cancers. CCOCs tend to occur in the fifth to seventh decades of life, with only 10% of cases occurring in the fourth decade. On the other side, papillary thyroid carcinoma is the most common histology type of thyroid carcinoma and is associated with locoregional spread.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!